Boston Heart Diagnostics Launches LipidSeq™-- An NGS Test for Common Genetic Disorders of Lipid Metabolism
Retrieved on:
Wednesday, August 17, 2022
LCAT, Robarts Research Institute, Triglyceride, Cardiovascular disease, Multimedia, Disorder, Risk, Apolipoprotein, Lists of diseases, Hypercholesterolemia, HDL, Lipid metabolism, Tangier disease, Hypertriglyceridemia, Patient, View, NGS, Kidney, Sitosterolemia, Mutation, Lipidology, Health, Disease, Health care, Pharmaceutical industry, Eurofins Scientific, Familial dysbetalipoproteinemia
This saliva-based NGS test identifies the most common genetic causes of lipid and lipoprotein disorders.
Key Points:
- This saliva-based NGS test identifies the most common genetic causes of lipid and lipoprotein disorders.
- Boston Heart Diagnostics announces the launch of LipidSeq, a revolutionary genetic test for cardiovascular disease.
- Boston Heart is the only commercial laboratory able to test biochemical and genetic contributors when diagnosing inherited disorders of lipid metabolism (Reference: Schaefer EJ, Geller AS, Endress G. The biochemical and genetic diagnosis of lipid disorders.
- For more information on Boston Heart Diagnostics, please visit www.BostonHeartDiagnostics.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/boston-heart-diagnostics-launch...